Reactions after pertussis vaccine: a manufacturer's experiences and difficulties since 1964
- PMID: 205305
- PMCID: PMC1603528
- DOI: 10.1136/bmj.1.6116.809
Reactions after pertussis vaccine: a manufacturer's experiences and difficulties since 1964
Abstract
Pertussis vaccines vary in quality, safety, and efficacy according to the production strains of Bordetella pertussis, the method of manufacture, and quality control procedures. It is therefore not justifiable to combine information on the incidence, nature, and severity of reactions after all manufacturers' pertussis vaccines as if they were a single product. Attempts were made to collect information on all suspected cases of severe reactions that occurred after administration of about 15 million doses of Wellcome pertussis vaccines in the United Kingdom and Northern Ireland from 1964 to mid-1977. Altogether six deaths, six neurological reactions with sequelae, and 17 convulsions without sequelae were reported, but some were clearly not attributable to the vaccine, while, in other cases, the available information was inadequate for assessing the role of vaccination. Neurological disorders, similar to those reported in a few children after pertussis vaccination, occur unexpectedly in apparently healthy infants at the recommended age for immunisation, so chance association between vaccination and these events can be expected in some children. The Joint Committee on Vaccination and Immunisation has made several recommendations aimed at reducing severe reactions after pertussis vaccination. These include replacing plain vaccine with aluminium-adsorbed vaccine, but there is no clear evidence that the aluminium-adsorbed vaccine produces fewer reactions than the plain.There are difficulties enough in deciding the cause of events that occur after vaccination, since these reactions often occur naturally in children of vaccination age. The task is made even harder by the assumption that various manufacturers' vaccines are the same and the lack of information available to manufacturers about cases in which their vaccine has been implicated. Information on vaccines administered is entered on immunisation records cards; it should be used and referred to if reactions occur.
Similar articles
-
Permanent brain damage and pertussis vaccination: is the end of the saga in sight?Vaccine. 1989 Jun;7(3):199-210. doi: 10.1016/0264-410x(89)90229-6. Vaccine. 1989. PMID: 2571213
-
Role of whole-cell pertussis vaccine in severe local reactions to the preschool (fifth) dose of diphtheria-pertussis-tetanus vaccine.CMAJ. 1994 Jan 1;150(1):29-35. CMAJ. 1994. PMID: 8275406 Free PMC article. Clinical Trial.
-
Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 1997 Mar 28;46(RR-7):1-25. MMWR Recomm Rep. 1997. PMID: 9091780
-
Whole-cell and acellular pertussis vaccines.Ann Pharmacother. 1994 Jul-Aug;28(7-8):925-39. doi: 10.1177/106002809402800718. Ann Pharmacother. 1994. PMID: 7949515 Review.
-
Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.Paediatr Drugs. 2000 Mar-Apr;2(2):139-59. doi: 10.2165/00148581-200002020-00007. Paediatr Drugs. 2000. PMID: 10937466 Review.
Cited by
-
Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.Clin Microbiol Rev. 2005 Apr;18(2):326-82. doi: 10.1128/CMR.18.2.326-382.2005. Clin Microbiol Rev. 2005. PMID: 15831828 Free PMC article. Review.
-
Applied microbiology and biotechnology uncovering the biosynthetic pathway of polysaccharide-based microbial flocculant in Agrobacterium tumefaciens F2.Appl Microbiol Biotechnol. 2020 Oct;104(19):8479-8488. doi: 10.1007/s00253-020-10850-2. Epub 2020 Aug 24. Appl Microbiol Biotechnol. 2020. PMID: 32830292
-
Should public health take over immunization?Can Fam Physician. 1985 Jan;31:25. Can Fam Physician. 1985. PMID: 21279139 Free PMC article. No abstract available.
-
Two physically and serologically distinct lipopolysaccharide profiles in strains of Bordetella pertussis and their phenotype variants.Infect Immun. 1984 Jan;43(1):224-32. doi: 10.1128/iai.43.1.224-232.1984. Infect Immun. 1984. PMID: 6317567 Free PMC article.
-
Immunization of children in Calgary.Can Med Assoc J. 1984 Oct 15;131(8):844-6. Can Med Assoc J. 1984. PMID: 6488107 Free PMC article. No abstract available.
References
-
- Br Med J. 1945 Aug 18;2(4415):205-8 - PubMed
-
- Am J Public Health Nations Health. 1949 Feb;39(2):179-84 - PubMed
-
- Am J Public Health Nations Health. 1947 Jul;37(7):803-10 - PubMed
-
- Am J Public Health Nations Health. 1946 Apr;36(4):371-6 - PubMed
-
- Am J Public Health Nations Health. 1936 Nov;26(11):1097-105 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources